The short answer
Menopause is biologically the same transition for Black and African women, but research shows real differences in experience and care. In the SWAN study, African American women had the longest-lasting hot flashes, a median of about 10 years, and fibroids are more common, which can shape bleeding in perimenopause. Black women are also less often offered hormone therapy. The same evidence-based treatments are available, and you deserve to be heard and offered them.
No advertising or analytics trackers run on Specialized Care pages. Reading them is never linked to your identity. Our privacy pledge
Being seen and heard
Many Black women describe having symptoms dismissed, or being told to push through. Distrust of the medical system has real historical roots, and it should be met with respect and transparency, not impatience. This guide is written for women of the African diaspora: African American, African immigrant from Nigeria, Ghana, Ethiopia, Somalia and beyond, and Caribbean. Faith, language and family traditions vary widely across these communities.
Menopause is the same biological transition for every woman. Heritage and faith can shape how you want care delivered, and a few health risks do vary with ancestry. Both belong in your care plan; neither replaces an individual evaluation.
Longer and more intense hot flashes
The Study of Women’s Health Across the Nation (SWAN), a long-running NIH-funded study, found that African American women reported hot flashes and night sweats for the longest time of any group studied, a median of about 10 years. Symptoms also often started earlier in the transition. The reasons are likely a mix of biology, stress and social factors. Long-lasting symptoms are a reason to discuss treatment, not a reason to wait them out.
Fibroids and perimenopausal bleeding
Uterine fibroids are very common, and research has found that by age 50 more than 80 percent of Black women had developed them. In perimenopause, fibroids can contribute to heavy or prolonged bleeding and anemia. Fibroids usually shrink after menopause. Hormone therapy is not ruled out by fibroids, but dose, type and monitoring may be adjusted. Very heavy bleeding, or any bleeding after 12 months without a period, should be evaluated.
Heart, blood pressure and metabolic health
Black women in the U.S. have higher rates of high blood pressure, and heart disease is the leading cause of death. Menopause raises cardiovascular risk further. Regular blood pressure, cholesterol and glucose checks, and treating high blood pressure well, are among the most important parts of midlife care. These checks also shape which menopause treatments fit best.
Bone health
Average bone density tends to be higher in Black women, but osteoporosis and fractures still happen, and outcomes after hip fracture can be worse. Screening recommendations apply to all women aged 65 and older, and to younger postmenopausal women with risk factors. Vitamin D levels are often lower in people with darker skin; whether to test or supplement is an individual decision.
Closing the treatment gap
- Research has found Black women are less likely to be offered or use menopausal hormone therapy
- Ask directly about every option, hormonal and non-hormonal
- Bring a symptom list and how symptoms affect work, sleep and relationships
- You can request a different clinician if you do not feel heard
Faith, family and community
Church, mosque and community networks are central for many women and can be powerful sources of support and health information. Our Christian and Muslim women’s guides cover faith-specific practices such as fasting. Family involvement is your choice. Traditional remedies may be part of family life; tell your clinician what you take so interactions can be checked.
Treatment options are the same
There is no separate menopause protocol based on race or heritage. Hormone therapy, including transdermal estradiol, and non-hormonal options such as fezolinetant, elinzanetant, SNRIs and gabapentin are considered based on your history and preferences.
How Kindr approaches this
- We ask about your background and preferences instead of assuming them
- Every option is discussed openly, so that no one is under-offered treatment
- You choose who joins your care decisions
- Clinical decisions are made by licensed clinicians based on evidence and your own health history
Specialized care pathway
Care that respects your values
A licensed Kindr clinician can review your symptoms and health history, listen to your preferences, and discuss options, including hormone therapy or non-hormonal treatment, when medically appropriate.
Questions, answered
Common questions
Do Black women have worse menopause symptoms?
+
In the SWAN study, African American women reported hot flashes for the longest duration, a median of about 10 years, and often more bothersome symptoms. Experiences vary individually.
Can I take HRT if I have fibroids?
+
Often, yes. Fibroids do not automatically rule out hormone therapy, but they can affect bleeding, so the dose, type and follow-up are tailored. Heavy bleeding should be evaluated first.
Do fibroids go away after menopause?
+
Fibroids usually shrink after menopause as estrogen falls. Hormone therapy can slow that shrinkage in some women, which a clinician monitors.
Why are Black women less likely to get hormone therapy?
+
Studies have found lower rates of HRT offers and use among Black women, linked to differences in how symptoms are discussed and treated. Asking directly about all options helps close the gap.
Do Black women need bone density scans?
+
Yes. Screening is recommended for all women 65 and older and for younger postmenopausal women with risk factors, regardless of race. Average density is higher, but fractures still occur.
WRITTEN & MEDICALLY REVIEWED BY
Kindr Health Clinical Team
Kindr Health Inc. — Editorial & Clinical Team, led by Kevin Wolfe, CMO
Kindr’s clinical content is written and reviewed by board-certified clinicians who prescribe hormone therapy every day across all 50 states — menopause-focused physicians, nurse practitioners, and pharmacists working under Kindr Health, Inc.’s organizational clinical oversight. Every page is checked against current NAMS and ACOG guidance, FDA labeling, and the primary literature before publication, then re-reviewed on a rolling schedule when guidance changes.
Organizational NPI 1609792902 · Last reviewed October 5, 2026 · Editorial policy
Educational content only — not a substitute for individual medical advice, diagnosis, or treatment.
SOURCES & REFERENCES
Every clinical claim on this page is sourced.
- Study of Women’s Health Across the Nation (SWAN) — SWAN multi-site longitudinal study, funded by the National Institutes of Health. www.swanstudy.org
- Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition (Avis NE, et al.) (2015) — JAMA Internal Medicine. doi.org/10.1001/jamainternmed.2014.8063
- High cumulative incidence of uterine leiomyoma in black and white women (Baird DD, et al.) (2003) — American Journal of Obstetrics and Gynecology. doi.org/10.1067/mob.2003.99
- The 2022 Hormone Therapy Position Statement of The North American Menopause Society (2022) — The Menopause Society. www.menopause.org/docs/default-source/professional/nams-2022-hormone-therapy-position-statement.pdf
- The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society (2023) — Menopause (journal of The Menopause Society). pubmed.ncbi.nlm.nih.gov/?term=2023+nonhormone+therapy+position+statement+North+American+Menopause+Society
- Osteoporosis to Prevent Fractures: Screening — U.S. Preventive Services Task Force. www.uspreventiveservicestaskforce.org/uspstf/recommendation/osteoporosis-screening